- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: lurbinectedin.
Displaying page 1 of 1.
EudraCT Number: 2021-004471-13 | Sponsor Protocol Number: PM1183-C-008-21 | Start Date*: 2022-08-03 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps... | |||||||||||||
Medical condition: Small Cell Lung Cancer (SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing) HU (Ongoing) IT (Ongoing) AT (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001016-11 | Sponsor Protocol Number: SAKK17/16 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:SAKK | |||||||||||||
Full Title: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial | |||||||||||||
Medical condition: Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003602-16 | Sponsor Protocol Number: PM1183-A-014-15 | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:PHARMA MAR, S.A. SOCIEDAD UNIPERSONAL | |||||||||||||
Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors. | |||||||||||||
Medical condition: Selected Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) DE (Ongoing) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001930-20 | Sponsor Protocol Number: GO43104 | Start Date*: 2022-02-09 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL... | |||||||||||||
Medical condition: Small-Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) HU (Ongoing) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001114-19 | Sponsor Protocol Number: IB2022-01 | Start Date*: 2023-04-03 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer | |||||||||||||
Medical condition: platinum sensitive extensive stage small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000206-18 | Sponsor Protocol Number: PM1183-B-005-14-QT | Start Date*: 2015-09-10 | |||||||||||
Sponsor Name:PharmaMar S.A., Sociedad Unipersonal | |||||||||||||
Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors | |||||||||||||
Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003773-42 | Sponsor Protocol Number: PM1183-B-005-14 | Start Date*: 2015-03-30 | |||||||||||
Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal | |||||||||||||
Full Title: A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors. | |||||||||||||
Medical condition: Selected Advanced Solid Tumors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) SE (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001641-89 | Sponsor Protocol Number: PM1183-C-003-14 | Start Date*: 2016-06-28 | |||||||||||
Sponsor Name:Pharma Mar S.A. | |||||||||||||
Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients w... | |||||||||||||
Medical condition: Small-Cell Lung Cancer (SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed) PT (Completed) CZ (Completed) NL (Completed) BG (Completed) GB (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005251-39 | Sponsor Protocol Number: PM1183-C-004-14 | Start Date*: 2015-06-15 | ||||||||||||||||
Sponsor Name:Pharma Mar S.A., Sociedad Unipersonal | ||||||||||||||||||
Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial) | ||||||||||||||||||
Medical condition: Platinum-resistant ovarian cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) AT (Completed) BE (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002261-35 | Sponsor Protocol Number: MedOPP300 | Start Date*: 2020-03-03 | |||||||||||
Sponsor Name:Dr.Antonio Calles Blanco | |||||||||||||
Full Title: “Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER stu... | |||||||||||||
Medical condition: Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000548-25 | Sponsor Protocol Number: PM1183-B-004-13 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal | |||||||||||||
Full Title: A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Sm... | |||||||||||||
Medical condition: Unresectable Non-Small Cell Lung Cancer (NSCLC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001141-80 | Sponsor Protocol Number: POLA/ACOG1401 | Start Date*: 2015-07-27 |
Sponsor Name:Andrés Poveda | ||
Full Title: Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors | ||
Medical condition: Advanced or metastatic solid tumors (Phase I) Patients with potential tumors with possibly sensitivity to PARP inhibitors according to histology, or patients with molecular features (Phase II) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001553-12 | Sponsor Protocol Number: 2SMALL | Start Date*: 2019-11-28 |
Sponsor Name:Fundacion ONCOSUR | ||
Full Title: Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-B... | ||
Medical condition: Histologically or cytologically confirmed diagnosis of extensive or limited SCLC. Progression to first-line platinum-based chemotherapy. Measurable disease according to RECIST v.1.1. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024292-30 | Sponsor Protocol Number: PM1183-B-001-10 | Start Date*: 2011-09-05 | |||||||||||
Sponsor Name:Pharma Mar, S.A. Sociedad Unipersonal | |||||||||||||
Full Title: A Phase II Study of PM01183 as Second-line Treatment in Patients with Metastatic Pancreatic Cancer | |||||||||||||
Medical condition: Metastatic Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.